Form 4: Precision BioSciences CEO Michael Amoroso Reports Stock Transactions
SEC Form 4 Filing
Michael Amoroso, CEO of Precision BioSciences, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On November 2, 2024, Michael Amoroso, the President and CEO of Precision BioSciences, had 9,443 Restricted Stock Units (RSUs) vest.
- Following the vesting, Amoroso sold 3,012 shares on November 4, 2024, at a price of $8.19 per share to cover tax withholding obligations.
- After these transactions, Amoroso directly owns 28,537 shares of Precision BioSciences common stock and 9,444 RSUs.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions related to stock-based compensation. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is primarily driven by tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/02/2022 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023. |
| 11/02/2023 | First vesting date of RSUs granted on November 2, 2022. |
| 11/02/2024 | Vesting of 9,443 Restricted Stock Units (RSUs). |
| 11/04/2024 | Sale of 3,012 shares at $8.19 per share to cover tax obligations. |
| 11/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.